

House \_\_\_\_\_ Amendment NO. \_\_\_\_\_

Offered By \_\_\_\_\_

1 AMEND House Committee Substitute for Senate Substitute for Senate Bill No. 262, Page 2, Section 334.108,  
2 Line 26, by inserting after all of said section and line the following:

3 "338.321. 1. The "Missouri Oral Chemotherapy Parity Interim Committee" is hereby created to study  
4 the disparity in patient co-payments between orally and intravenously administered chemotherapies, the  
5 reasons for the disparity, and the patient benefits in establishing co-payment parity between oral and infused  
6 chemotherapy agents. The committee shall consider information on the costs or actuarial analysis associated  
7 with the delivery of patient oncology treatments. The conclusions of this study shall satisfy any statutorily  
8 required actuarial analysis.

9 2. The Missouri oral chemotherapy parity interim committee shall consist of the following members:

10 (1) Two members of the senate, appointed by the president pro tempore of the senate;

11 (2) Two members of the house of representatives, appointed by the speaker of the house of  
12 representatives;

13 (3) One member who is an oncologist or physician with expertise in the practice of oncology licensed  
14 in this state under chapter 334;

15 (4) One member who is an oncology nurse licensed in this state under chapter 335;

16 (5) One member who is a representative of a Missouri pharmacy benefit management company;

17 (6) One member from an organization representing licensed pharmacists in this state;

18 (7) One member from the business community representing businesses on health insurance issues;

19 (8) One member from an organization representing the leading research-based pharmaceutical and  
20 biotechnology companies;

21 (9) One patient advocate;

22 (10) One member from the organization representing a majority of hospitals in this state;

23 (11) One member from a health carrier as such term is defined under section 376.1350;

24 (12) One member from the organization representing a majority of health carriers in this state, as such  
25 term is defined under section 376.1350; and

26 (13) One member from the Leukemia and Lymphoma Society.

27 3. All members, except for the members from the general assembly, shall be appointed by the  
28 governor no later than September 1, 2013. The department of insurance, financial institutions and  
29 professional registration shall provide assistance to the committee.

30 4. No later than January 1, 2014, the committee shall submit a report to the governor, the speaker of  
31 the house of representatives, the president pro tempore of the senate, and the appropriate legislative committee  
32 of the general assembly regarding the results of the study and any legislative recommendations."; and  
33

34 Further amend said bill by amending the title, enacting clause, and intersectional references accordingly.  
35

Action Taken \_\_\_\_\_ Date \_\_\_\_\_